How do Ozempic and Trulicity work?
Both Ozempic (semaglutide) and Trulicity (dulaglutide) are GLP-1 receptor agonists that mimic the hormone GLP-1 to boost insulin release, slow digestion, and reduce appetite for blood sugar control in type 2 diabetes. Ozempic activates receptors more potently due to semaglutide's structure, leading to stronger weight loss effects in trials.[1]
What conditions do they treat?
Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in patients with heart disease; it also has a higher dose version (Wegovy) for weight loss. Trulicity covers type 2 diabetes and cardiovascular risk reduction but lacks a dedicated weight management approval.[1][2]
How are they administered and dosed?
Ozempic comes as a weekly subcutaneous injection via a prefilled pen, starting at 0.25 mg and titrating to 2 mg max. Trulicity uses a similar weekly pen but with simpler fixed doses: 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg, requiring less titration.[1][2]
| Feature | Ozempic (semaglutide) | Trulicity (dulaglutide) |
|------------------|--------------------------------|-------------------------------|
| Dose frequency | Weekly injection | Weekly injection |
| Starting dose | 0.25 mg (titrate up) | 0.75 mg (fixed options) |
| Max dose | 2 mg | 4.5 mg |
| Pen design | Dial-up dosing | Autoinjector, no dialing |
How effective are they for blood sugar and weight loss?
Head-to-head trials like SUSTAIN 7 show Ozempic reduces A1C more (1.5-1.8% drop) than Trulicity (1.4%) and drives greater weight loss (8-10 lbs vs. 6-7 lbs over 40 weeks). Both lower cardiovascular events similarly in large outcomes studies.[3]
What side effects should patients expect?
Common issues overlap: nausea (20-40% for both), vomiting, diarrhea, and injection-site reactions. Ozempic reports slightly higher nausea rates during dose escalation; Trulicity may cause less GI upset long-term. Both carry boxed warnings for thyroid tumors (from rodent data) and risks like pancreatitis.[1][2]
How much do they cost without insurance?
Ozempic lists at $936 for four weekly doses; Trulicity at $987. Savings cards often drop both under $25/month for eligible patients, but coverage varies by plan.[4]
Who makes them and when do patents expire?
Eli Lilly manufactures Trulicity; Novo Nordisk makes Ozempic. Key U.S. patents expire in 2033 for Trulicity's composition and 2031-2032 for Ozempic's, with ongoing litigation over formulation patents delaying generics.5
[1]: Ozempic Prescribing Information, FDA.gov
[2]: Trulicity Prescribing Information, FDA.gov
[3]: SUSTAIN 7 Trial, Diabetes Care (2018)
[4]: GoodRx pricing data (as of 2023)